FMC Corporation filings document the regulatory record of a NYSE-listed agricultural sciences company with common stock trading under FMC. Recent 8-K reports disclose operating results, material credit-agreement amendments, financial covenants, subsidiary guarantees, collateral arrangements, dividend limitations, restructuring charges, and governance changes.
Proxy materials describe annual meeting matters, stockholder voting procedures, and equity incentive plan approvals. Together, the filings cover FMC's capital structure, board oversight, compensation programs, manufacturing footprint actions, risk-related covenant terms, and recurring financial reporting for its crop protection business.
FMC Corporation sold 30,319,166 common shares to Tessenderlo Group NV in a private placement on September 23, 2026, at $13.30 per share for an aggregate purchase price of $403,244,907.80. Tessenderlo had owned 790,000 shares before the purchase and reported beneficial ownership of 31,109,166 shares, or 20.0% of FMC's 155,552,366 shares outstanding as of September 23, 2026. Luc Jules R Tack, Tessenderlo's chief executive officer, may also be deemed to share beneficial ownership of Tessenderlo's shares.
Under the investor agreement, Tessenderlo may nominate one candidate for appointment and election as an independent director and designate one non-voting board observer; it nominated Luc Jules R Tack and Miguel de Potter, respectively. Pre-emptive rights apply while Tessenderlo holds at least 10% of FMC's outstanding shares, and pre-emptive and top-up rights are subject to a 20% maximum ownership percentage. Transfer restrictions run through September 23, 2029, and Tessenderlo intends to exercise its top-up rights.
FMC Corp reports Tessenderlo Group NV as the direct beneficial owner of 31,109,166 shares of common stock as of September 23, 2026; Luc Jules R Tack is identified as an indirect beneficial owner through his control of Oostiep Group bv, Tessenderlo Group NV’s controlling shareholder. Tessenderlo Group NV is identified as a director and 10% owner, and Tack as a 10% owner. Under an Investor Agreement dated September 23, 2026, Tessenderlo has the right to nominate one member of FMC’s board and may be deemed a “director by deputization” for Section 16 purposes.
FMC Corporation completed the sale to Tessenderlo Group NV of 30,319,166 common shares at $13.30 per share, for an aggregate purchase price of $403,244,907.80, on September 23, 2026. Tessenderlo now owns approximately 20.0% of FMC’s outstanding common stock. For as long as Tessenderlo holds at least 10.0%, FMC will add one Board seat at its first regularly scheduled Board meeting after closing and appoint a nominee selected by Tessenderlo; Tessenderlo also has one Board-observer right while it meets that threshold. Tessenderlo has nominated Luc Tack, its chief executive officer, for the Board seat.
For 36 months after closing, Tessenderlo and its affiliates are restricted from transferring or hedging their common-stock exposure, subject to exceptions. After that period, transfers to a competitor, an activist, or a transferee that would hold 4.9% or more are restricted, subject to exceptions. FMC granted eight demand registration rights, exercisable no more than once every 120 days. At an ownership level of at least 10.0%, Tessenderlo also has preemptive rights on certain equity issuances and may acquire shares during specified periods to maintain 20.0% ownership, subject to termination in certain circumstances.
FMC CORP (FMC) reported that Corporate Controller Nicholas Pfeiffer sold 1,251 shares of common stock on September 9, 2026 at $12.775 per share in an open-market or private transaction. After this sale, he held 28,513 shares directly and 549.962 shares indirectly through a Thrift Plan based on a statement as of September 9, 2026. No Rule 10b5-1 trading plan is reported.
FMC CORP (FMC) received a Rule 144 notice indicating that officer Nicholas L. Pfeiffer, through Fidelity Brokerage Services LLC, has arranged the potential sale of 1,251 shares of common stock of FMC on the NYSE as of September 9, 2026.
The shares relate to prior restricted stock vesting events from February 2022 and February 2023, including tranches of 9, 645 and 597 shares granted as compensation by FMC.
State Street Corporation reported beneficial ownership of 6,508,613 shares of FMC Corp common stock, representing 5.2% of the class as of June 30, 2026. These shares are held with no sole voting or dispositive power, but with 6,138,301 shares under shared voting power and 6,508,613 shares under shared dispositive power.
The position is held through various State Street asset management and trust subsidiaries, including SSGA Funds Management, Inc. and State Street Bank and Trust Company, among others. No other person is identified as having a more-than-5% economic interest through rights to dividends or sale proceeds.
For the quarter ended June 30, 2026, FMC Corporation reported revenue of $867.1 million, down from $1,050.5 million a year earlier, and a net loss attributable to stockholders of $186.6 million versus prior net income of $66.7 million. Diluted EPS was $(1.49), including $222.3 million of restructuring and other charges tied to Project Foundation, manufacturing exits, the India business held for sale and environmental items.
For the first half of 2026, FMC generated revenue of $1,625.7 million and a net loss of $467.9 million, with $299.3 million of restructuring and other charges and an additional $123 million valuation allowance on Swiss deferred tax assets. Operating cash flow from continuing operations was $(237.9 million). The company issued $1.2 billion of 8.0% Senior Secured Notes due 2031, received a $200.0 million prepurchase payment under a rimisoxafen license with Corteva, and ended June 30, 2026 with $476.6 million of cash and $4,280.6 million of total debt.
FMC Corporation reported second quarter 2026 revenue of $867.1 million, down 17% versus Q2 2025, with revenue excluding India down 20% and organic revenue down 22%. The company posted a GAAP net loss attributable to stockholders of $186.6 million, or $(1.49) per diluted share, versus earnings of $0.53 a year earlier. Adjusted EBITDA was $152.6 million, down 26%, and adjusted EPS was $0.26, down 62%.
Operating cash flow improved sharply to $363.0 million, driving free cash flow of $357.4 million versus $39.7 million in Q2 2025, aided by a $200 million rimisoxafen licensing payment. FMC outlined actions expected to generate approximately $1 billion of proceeds for debt reduction, including a $252 million India commercial business sale, $200 million rimisoxafen license, $114 million Newark sale-leaseback, and a $400 million equity investment from Tessenderlo Group. Full-year 2026 guidance was lowered: revenue excluding India is now $3.50–$3.70 billion, adjusted EBITDA $620–$680 million, and adjusted EPS $1.19–$1.49, all down materially versus 2025, with a return to year-over-year growth expected in Q4.
BlackRock, Inc. reports beneficial ownership of common stock of FMC Corporation on a Schedule 13G/A (Amendment No. 20) as of June 30, 2026. BlackRock and its reporting business units beneficially own 19,345,361 FMC common shares, representing 15.5% of the class.
BlackRock has sole voting power over 19,137,958 shares and sole dispositive power over 19,345,361 shares, with no shared voting or dispositive power. The filing notes that one client vehicle, iShares Core S&P Small-Cap ETF, has an interest in FMC common stock exceeding five percent of the total outstanding common stock. The schedule is signed on behalf of BlackRock by a Managing Director, supported by a power of attorney.
FMC Corp reports that Pierre R. Brondeau, Chairman, CEO and President, acquired 44 shares of common stock on July 16, 2026. The shares were issued at no cost as dividend equivalent rights tied to vested restricted stock units, bringing his direct holdings to 533,913 shares.